A newly discovered brain hormone called CCN3 could transform osteoporosis treatment by directly rebuilding bone density and strength, rather than simply slowing bone loss as current medications do. Scientists at UC Davis Health and UC San Francisco identified this molecule, also known as the Maternal Brain Hormone, in research published in Nature. The discovery offers hope to roughly 33 million American adults living with osteoporosis or osteoarthritis, two degenerative conditions that weaken bones and joints and often lead to fractures and joint replacement surgery.

What Makes This Discovery Different From Current Osteoporosis Treatments?

Most osteoporosis medications work by slowing bone loss, but they don't rebuild bone tissue. CCN3 operates through an entirely different mechanism. Instead of just protecting existing bone, it directly activates skeletal stem cells, which are the body's bone-building cells, to form new bone tissue. In mouse studies, researchers found that the amount of bone formed was nearly three times the amount seen in untreated mice. This represents a fundamentally new approach to treating a disease that affects millions of people worldwide.

The research builds on two decades of UC Davis work into how hormones regulate bone health. Early studies found that removing progesterone receptors activated bone-forming cells, hinting at a hormonal pathway. Years later, researchers at UCSF discovered that blocking a specific estrogen receptor in the hypothalamus, a region of the brain that controls many body functions, caused female mice to develop unusually strong bones. The multidisciplinary team then identified CCN3 as the key hormone released by the hypothalamus to trigger this bone formation.

How Could CCN3 Help Fracture Healing in Older Adults?

One of the most promising applications involves accelerating bone repair in elderly patients, who often experience slow or incomplete fracture healing. In mouse models, researchers delivered CCN3 through a hydrogel patch, a thin, flexible material applied to the injury site. The treatment significantly accelerated bone repair, suggesting that future therapies could reduce complications, improve mobility and independence, and speed recovery after fractures in older adults. This could have major implications for preventing the disability and loss of independence that often follows fractures in aging populations.

The discovery also revealed why CCN3 exists in the first place. Its natural role is closely linked to protecting women's bones during breastfeeding. The increased calcium demand during lactation can weaken skeletal integrity, and CCN3 appears to be the body's built-in mechanism to counteract this bone loss.

Ways to Understand How This Hormone Protects Bone Health

• Skeletal Stem Cell Activation: CCN3 directly signals bone-building stem cells to differentiate and form new bone tissue, rather than simply preventing bone loss like current drugs.
• Lactation Protection: The hormone evolved to protect women's bones during breastfeeding by counteracting the calcium demands that naturally weaken skeletal integrity during this period.
• Cartilage Regeneration Potential: Researchers have found that CCN3 signaling may also guide stem cells to form stable cartilage, potentially preventing or reversing osteoarthritis damage in joints.

Beyond osteoporosis, the research opens doors to treating osteoarthritis, a condition affecting millions of Americans. Researchers have developed an approach using controlled microinjuries to activate local stem cells and guide them to form stable cartilage by leveraging CCN3 signaling. This strategy could eventually help prevent osteoarthritis in younger athletes and middle-aged individuals with significant cartilage damage, or enable regeneration of lost joint cartilage.

"CCN3 directly activates skeletal stem cells to form new bone, offering a potential new class of therapies that could increase bone density, strengthen fragile bone and reduce fracture risk in aging populations," noted researchers at UC Davis Health and UC San Francisco.

UC Davis Health and UC San Francisco Research Team

The research was supported by federal funding from the National Institute of Health, including grants from the National Institute on Aging and the National Institute of Diabetes and Digestive and Kidney Diseases. This funding enabled the training and research of multiple young investigators involved with the study.

The next steps involve determining which brain signals activate or suppress CCN3 and evaluating whether it will be an effective bone-building agent to treat osteoporosis in humans. Researchers have already submitted grant applications to advance these studies further. Additionally, some of the research team has co-founded a company to accelerate the clinical translation of their findings, with the patented technology exclusively licensed through the University of California. While human trials are still ahead, this discovery represents a significant shift in how scientists think about treating bone disease, moving from slowing loss to actively rebuilding bone strength.